: Diabetic nephropathy is a common complication of diabetes mellitus type2. The mechanism involved is include changes in blood vessel that supply peripheral nerves and metabolic disorder such as increased or activation polyol pathway and non-enzymatic glycation. This study was aimed to Evaluate Fibroblast growth factor 23 (FGF23) in kidney damage susceptibility Correlation of theses markers with disease progression in Diabetic nephropathy patients. This case-control study was carried out on patients who attended multi teaching centers (Baghdad Teaching Hospital and Ghazi Al Harriry Teaching Hospital) for the period from April 2018 to June 2019. The subject which enrolled in this study was 90. The patients were 90 (55 males and 35 females), whose ages ranged from (50 to 82) years. They diagnosed as having CKD and DM based on previous medical reports, laboratory tests and clinical examination by consultant nephrologist. The results of those patients were compared with (30) DM only persons whose ages ranged from (50-82) years (17 males and 13 females), 30 CKD and DM with normal microalbumuria whose ages ranged from (50-82) years (18 males and 12 females), as a control group and 30 DM, CKD and abnormal microalbumuria. The following tests were applied for all the patients and the control groups; they were evaluated by different laboratory methods: Serum fibroblast growth factor 23 Serum urea, Serum creatinine, and Albumin / creatinine ratio. The level of fasting blood sugar (F.BS) show (P<0.05) significance difference among the three groups with the higher level in the DMT2 with macroalbumin compared with the two other groups DMT2 with microalbumin and the DMT2 without albumin nephropathy. Control Correlation tests between FGF23 and (BMI Kg/m2, Urea mg/dl, Creatinine mg/dl and Alb:creatinine mg/g ) among DMT2 and without nephropathy (Control) , DMT2 with micro-albumin and DMT2 with macro-albumin show significant at baseline. From this study, it can conclude that: the measurement of serum FGF23 was of clinical value in assessment of renal damage that associated with DMT2 patients between the baseline time and after 6 months.